121 related articles for article (PubMed ID: 25716545)
1. Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations.
Adema V; Larráyoz MJ; Calasanz MJ; Palomo L; Patiño-García A; Agirre X; Hernández-Rivas JM; Lumbreras E; Buño I; Martinez-Laperche C; Mallo M; García O; Álvarez S; Blazquez B; Cervera J; Luño E; Valiente A; Vallespí MT; Arenillas L; Collado R; Pérez-Oteyza J; Solé F
Br J Haematol; 2015 Oct; 171(1):137-41. PubMed ID: 25716545
[No Abstract] [Full Text] [Related]
2. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
[TBL] [Abstract][Full Text] [Related]
3. Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression.
Fernandez-Mercado M; Pellagatti A; Di Genua C; Larrayoz MJ; Winkelmann N; Aranaz P; Burns A; Schuh A; Calasanz MJ; Cross NC; Boultwood J
Br J Haematol; 2013 Oct; 163(2):235-9. PubMed ID: 23889083
[TBL] [Abstract][Full Text] [Related]
4. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression.
Hou HA; Kuo YY; Tang JL; Chou WC; Yao M; Lai YJ; Lin CC; Chen CY; Liu CY; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Feb; 89(2):181-6. PubMed ID: 24127063
[TBL] [Abstract][Full Text] [Related]
6. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.
Damm F; Itzykson R; Kosmider O; Droin N; Renneville A; Chesnais V; Gelsi-Boyer V; de Botton S; Vey N; Preudhomme C; Clavert A; Delabesse E; Park S; Birnbaum D; Fontenay M; Bernard OA; Solary E
Leukemia; 2013 Jun; 27(6):1401-3. PubMed ID: 23443343
[No Abstract] [Full Text] [Related]
7. SETBP1 mutation analysis in 944 patients with MDS and AML.
Thol F; Suchanek KJ; Koenecke C; Stadler M; Platzbecker U; Thiede C; Schroeder T; Kobbe G; Kade S; Löffeld P; Banihosseini S; Bug G; Ottmann O; Hofmann WK; Krauter J; Kröger N; Ganser A; Heuser M
Leukemia; 2013 Oct; 27(10):2072-5. PubMed ID: 23648668
[No Abstract] [Full Text] [Related]
8. SETBP1 mutations in juvenile myelomonocytic leukaemia and myelodysplastic syndrome but not in paediatric acute myeloid leukaemia.
Shiba N; Ohki K; Park MJ; Sotomatsu M; Kudo K; Ito E; Sako M; Arakawa H; Hayashi Y
Br J Haematol; 2014 Jan; 164(1):156-9. PubMed ID: 24117422
[No Abstract] [Full Text] [Related]
9. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
[TBL] [Abstract][Full Text] [Related]
10. Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes.
Melody M; Al Ali N; Zhang L; Ramadan H; Padron E; Sallman D; Sweet K; Lancet J; List A; Bennett JM; Komrokji R
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):324-328. PubMed ID: 32044274
[TBL] [Abstract][Full Text] [Related]
11. SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms.
Fabiani E; Falconi G; Fianchi L; Criscuolo M; Leone G; Voso MT
Haematologica; 2014 Sep; 99(9):e152-3. PubMed ID: 24907359
[No Abstract] [Full Text] [Related]
12. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.
Jädersten M; Saft L; Smith A; Kulasekararaj A; Pomplun S; Göhring G; Hedlund A; Hast R; Schlegelberger B; Porwit A; Hellström-Lindberg E; Mufti GJ
J Clin Oncol; 2011 May; 29(15):1971-9. PubMed ID: 21519010
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis.
Shou LH; Cao D; Dong XH; Fang Q; Wu Y; Zhang Y; Fei JP; Xu BL
PLoS One; 2017; 12(2):e0171608. PubMed ID: 28158286
[TBL] [Abstract][Full Text] [Related]
14. Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies.
Winkelmann N; Schäfer V; Rinke J; Kaiser A; Ernst P; Scholl S; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2511-2519. PubMed ID: 28913558
[TBL] [Abstract][Full Text] [Related]
15. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype.
Wang W; Routbort MJ; Tang Z; Ok CY; Patel KP; Daver N; Garcia-Manero G; Medeiros LJ; Wang SA
Eur J Haematol; 2017 Dec; 99(6):536-543. PubMed ID: 28926144
[TBL] [Abstract][Full Text] [Related]
16. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
[TBL] [Abstract][Full Text] [Related]
17. Study of p53 in elderly patients with myelodysplastic syndromes by immunohistochemistry and DNA analysis.
Kikukawa M; Aoki N; Sakamoto Y; Mori M
Am J Pathol; 1999 Sep; 155(3):717-21. PubMed ID: 10487829
[TBL] [Abstract][Full Text] [Related]
18. Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q).
Tefferi A; Idossa D; Lasho TL; Mudireddy M; Finke C; Shah S; Nicolosi M; Patnaik MM; Pardanani A; Gangat N; Hanson CA; Ketterling RP
Blood Cancer J; 2017 Dec; 7(12):658. PubMed ID: 29249799
[No Abstract] [Full Text] [Related]
19. Mutation of CDKN2 is infrequently detected in myelodysplastic syndrome.
Kaneko H; Horiike S; Nakao M; Yokota S; Sasai Y; Iwai T; Nakagawa H; Fujii H; Taniwaki M; Kashima K; Misawa S
Leukemia; 1997 Aug; 11(8):1391-2. PubMed ID: 9264400
[No Abstract] [Full Text] [Related]
20. Impact of TP53 mutation and 17p deletion in mantle cell lymphoma.
Halldórsdóttir AM; Lundin A; Murray F; Mansouri L; Knuutila S; Sundström C; Laurell A; Ehrencrona H; Sander B; Rosenquist R
Leukemia; 2011 Dec; 25(12):1904-8. PubMed ID: 21720382
[No Abstract] [Full Text] [Related]
[Next] [New Search]
